François Ferré

Acurion is revolutionizing frontline cancer care by equipping oncologists with critical genomic activity insights to get cancer patients onto the right treatments faster. The companys mission is to accelerate the translation of its life-saving AI technology into the clinical arena to make a real, immediate and profound difference in therapy for patients worldwide. Dedicated to improving patient outcomes, Acurion collaborates with leading research institutions, patient advocacy groups, and industry partners to advance precision oncology. Please visit www.acurionhealth.com to learn more.

At Neuralace Medical, we are driven to accelerate the world's transition to sustainable, non-invasive chronic pain relief. What do we believe that very few others do? We fundamentally believe that overcoming chronic pain is inevitable. With our bold vision, we are challenging the conventional thinking the healthcare industry is currently laden with to implement innovations and technological advances to improve the overall quality of life of individuals by maximizing pain relief and minimizing side-effects, redefining the very concept of pain therapy which can leave patients with more side-effects than benefits. NeuraLace is not just a device developer, but also a technology company with a focus on medical innovations that can significantly restore the quality of life patients suffering from chronic pain. Our inherent interest in innovation and deep technical knowledge, along with the partnerships we are currently developing, will allow us to realize our vision and create something truly special. We are a startup medical technology company here to make a dent in the world of pain therapeutics!

AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx). IDgenetix® is AltheaDx’s PGx product test for depression and anxiety and is supported by a published/peer-reviewed Randomized Controlled Trial that demonstrated clinical utility over standard of care when physicians used the test prior to prescribing a medication.

Acurion is revolutionizing frontline cancer care by equipping oncologists with critical genomic activity insights to get cancer patients onto the right treatments faster. The companys mission is to accelerate the translation of its life-saving AI technology into the clinical arena to make a real, immediate and profound difference in therapy for patients worldwide. Dedicated to improving patient outcomes, Acurion collaborates with leading research institutions, patient advocacy groups, and industry partners to advance precision oncology. Please visit www.acurionhealth.com to learn more.

At Neuralace Medical, we are driven to accelerate the world's transition to sustainable, non-invasive chronic pain relief. What do we believe that very few others do? We fundamentally believe that overcoming chronic pain is inevitable. With our bold vision, we are challenging the conventional thinking the healthcare industry is currently laden with to implement innovations and technological advances to improve the overall quality of life of individuals by maximizing pain relief and minimizing side-effects, redefining the very concept of pain therapy which can leave patients with more side-effects than benefits. NeuraLace is not just a device developer, but also a technology company with a focus on medical innovations that can significantly restore the quality of life patients suffering from chronic pain. Our inherent interest in innovation and deep technical knowledge, along with the partnerships we are currently developing, will allow us to realize our vision and create something truly special. We are a startup medical technology company here to make a dent in the world of pain therapeutics!

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

"Sometimes in science there are so many people trying to answer the same question that it's good to stray off in another direction,"​ Mitchell Kronenberg, Ph.D., LJI Chief Scientific Officer. "Taking the road less traveled can bring its voyagers to unexpected - and even groundbreaking - new territory."​ The La Jolla Institute The La Jolla Institute for Immunology is a non-profit medical research institute dedicated to increasing knowledge and improving human health through studies of the immune system. Our essential purpose is to expand our understanding of how the immune system works and to discover the causes of immune system disorders. The knowledge gained through our biomedical research can, in turn lead to the prevention, treatment and cure of a wide range of human diseases. What is immunology? Immunology is a broad branch of biomedical science that covers the study of all aspects of the immune response. The immune response is the defense system of the body carried out by white blood cells against microbial threats such as a virus infection. Since immunology has an effect on every organ system in our body, there is no biomedical discipline that has greater implications for improving human health. Where is LJI? The La Jolla Institute is located in the University of California San Diego's Science Research Park in a world-class facility covering 145,000 square feet. Our space provides an open laboratory setting that encourages La Jolla Institute for Immunology's highly collaborative research environment.